ABSTRACT
LIV-1(SLC39A6/ZIP6),primarily located on the cell membrane ,is one of the LZT subfami-ly members among the zinc transportprotein family .It possess six to eight transmembrane spanning domains ,with regions of concentrated histidine residues ,which has been shown to participate in the process of embryonic devel-opment as well as the growth and proliferation of tumors .It has been clearly established that LIV -1 played an important role in the development of esophageal squamous cell carcinoma and its overexpression ,which turned out to be a negative correlation upon the cancer′s prognosis has been verified to be a potent therapeutic target .Here-in,the advances of zinc transporter LIV -1 and the potential significance of the transporter to esophageal squa-mous cell carcinoma are reviewed .
ABSTRACT
Objective To investigate the protective effect of CBLB 502 on radiation pneumonitis and pulmonary fibrosis for confirming the feasibility of CBLB502 as a clinical anti-radiation drug release.Methods With a single 20 Gy irradia-tion, C57BL/6J mice was sacrificed on 24 h, 1 month, 3 months and 5 months and lung tissue was assayed by TUNEL method for apoptosis of alveolar epithelial cells and endothelial cells , HE staining showing fibrosis changes , immunohisto-chemistry detecting the expression of specific indicators , as well as pathological changes of the fur and skin radiated site . Results CBLB502 inhibits apoptosis in mice alveolar epithelial cells and vascular endothelial cells after irradiation , slowing the process of pulmonary fibrosis , while reducing the expression of laminin and maintaining the expression of surfac-tant protein B, and the skin inflammation also significantly reduced .Conclusion CBLB502 could alleviate the occurrence of radiation pneumonitis and pulmonary fibrosis as well as radiation-induced skin injury .